CERo Therapeutics Holdings, Inc. - Common Stock (CERO)
4.9850
+0.00 (0.00%)
NASDAQ · Last Trade: Sep 11th, 4:22 AM EDT
Detailed Quote
Previous Close
4.985
Open
-
Bid
4.500
Ask
5.620
Day's Range
N/A - N/A
52 Week Range
4.270 - 895.40
Volume
42
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
275,229
Chart
About CERo Therapeutics Holdings, Inc. - Common Stock (CERO)
CERo Therapeutics Holdings, Inc. is a biotechnology company that focuses on developing innovative therapies for serious medical conditions through advanced gene editing technologies. By leveraging proprietary platforms, the company aims to create transformative treatments that target the root causes of diseases, particularly in areas where current therapies are limited or lacking. CERo Therapeutics is dedicated to improving patient outcomes and advancing the field of precision medicine by working collaboratively with research institutions and healthcare professionals to ensure its solutions meet the highest standards of efficacy and safety. Read More
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technology
Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company’s lead cancer immunotherapy program
Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results
SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L with phagocytic mechanisms, today announces the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of lead compound CER-1236. Following an evaluation from the trial’s Dose Escalation Safety Committee, preliminary results show that the patient demonstrated no dose limiting toxicity. The Company anticipates dosing the second patient in the cohort shortly.
Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
